Key points from article :
Healthcare innovators set out to revolutionise radiotherapy for inoperable, and the most difficult to treat tumours.
Innovate UK brings together specialists in nanoparticle development, drug delivery and bioimaging.
Xerion Healthcare’s radiosensitiser heightens the cells’ sensitivity to radiotherapy while reducing side effects.
Active Needle Technology’s delivery system enables optimal distribution and limits damage of healthy cells.
Medicines Discovery Catapult’s (MDC) preclinical imaging validate its biodistribution in tumour and organs.
“Active Needles delivery offer the hope of recovery for vast numbers of patients” - Ian Quirk, CEO of Active Needle Technology.
“Ultrasonic delivery system and MDC optimise for maximum efficacy" - Gareth Wakefield, Chief Technology Officer, Xerion Healthcare.
It has never been more timely for research in this space to be undertaken.
